McGill IBD logo
Donate

Dr. Waqqas Afif


If you are interested in learning more about any of the clinical and research studies below or would like to volunteer as a research subject, please email: miirecherche.ibdresearch@muhc.mcgill.ca

Study Title: Switching to high-efficacy anti-IL-23 guselkumab in ustekinumab-exposed persons with active IBD: SHIFT-IBD


Study Title: EFFectiveness of Etrasimod on disease aCtivity and paTient-reported outcomes in Ulcerative Colitis: EFFECT-UC


Study Title: Pilot study to assess de-escalation of ustekinumab therapy in patients with Crohn’s disease and ulcerative colitis: UST De-Escalation


Study Title: Clinical, Biochemical, and Endoscopic Outcomes in Bio-Naïve Patients with Crohn’s Disease and Ulcerative Colitis Initiating Advanced Therapies


Study Title: Clinical, Endoscopic, and Histologic Outcomes in Patients with Eosinophilic Esophagitis Treated with Dupilumab


Study Title: IBD Disease Activity and Metabolic–Liver Markers Before and After Incretin Initiation: A Retrospective Study


Study Title: Correlation of drug concentrations and anti-drug antibodies with therapeutic outcomes in patients with Crohn’s Disease receiving infliximab or adalimumab for prevention of post-operative recurrence after ileal resection and ileo-colonic anastomosis (pending)


Study Title: Real-World Treatment Outcomes in Eosinophilic Esophagitis: A Comparative Analysis of Clinical, Endoscopic, and Histological Responses (pending)

Dr. Matthieu Allez


Study Title: PREdicting outcomes Following iLeocecal rEseCTion In CrOhN’s disease (The REFLECTION Study)

The REFLECTION study (PREdicting outcomes Following iLeocecal rEseCTIon in CrOhN’s disease) is an international research initiative led by investigators from Mount Sinai (NY), McGill University, Oxford, Aalborg University, and the REMIND consortium. The project aims to identify clinical, molecular, and environmental factors that determine why some patients remain disease-free after surgery while others experience recurrence.

Leveraging the unique REMIND cohort and large national databases from France and Denmark, REFLECTION combines detailed clinical data with cutting-edge multi-omic technologies, including transcriptomics, epigenetics, genetics, proteomics, immune profiling, and exposome analysis. By integrating these data, researchers seek to uncover the biological pathways underlying postoperative recurrence and develop tools that can predict patient outcomes more accurately.

A central goal of the project is to support more personalized treatment decisions. The findings could help identify patients who are most likely to benefit from early surgery, those who may require preventive therapy after surgery, and those who could avoid unnecessary treatment while remaining in remission.

The study is led by Matthieu Allez, Bruce Kaufman Chair in Inflammatory Bowel Disease Research, in collaboration with international experts in clinical epidemiology, immunology, and multi-omics. The project builds on the strengths of the REMIND cohort, one of the world’s largest prospective surgical Crohn’s disease cohorts with extensive long-term follow-up and biobanked samples.

By defining biomarkers and pathways associated with postoperative recurrence, REFLECTION aims to bring precision medicine to surgical Crohn’s disease care and improve outcomes for patients worldwide.


Study Title: AIRIS


Study Title: Proteomic and Transcriptomic Signatures for Predicting Sustained Remission and Disease Progression in Inflammatory Bowel Diseases (pending ethics approval)

Dr. Talat Bessisow


If you are interested in learning more about any of the clinical and research studies below or would like to volunteer as a research subject, please email: miirecherche.ibdresearch@muhc.mcgill.ca.

Collaboration with Dr. Jeffrey McCurdy, Ottawa Hospital Research Institute

Study Title: Evaluating fistula outcomes after seton removal in patients with perianal Crohn’s disease: UNFASTEN-PCD


Collaboration with Dr. Christopher Ma, MD MPH, University of Calgary

Study Title: Real-World Effectiveness and Safety of Upadacitinib for Achieving Endoscopic Remission in Moderate-to-Severely Active Ulcerative Colitis Phase IV: REMIT-UC


Collaboration with Dr. Bruce Mazer, McGill University Health Center

Study Title: Transdisciplinary Centre for Biological Therapies Biobank and Registry


Collaboration with Mayo Clinic Arizona

Study Title: Treat-to-Target of Endoscopic Remission in Patients with IBD in Symptomatic Remission: The QUOTIENT Trial


Collaboration with Dr. Neeraj Narula, Hamilton Health Sciences

Study Title: Comparison of medical RESCUE strategies for patients with steroid-refractory acute severe Ulcerative Colitis: an open-label randomized controlled trial: RESCUE-UC


Study Title: Effect of dietary nanomaterials on the development and disease progression of inflammatory bowel disease









Dr. Alain Bitton


If you are interested in learning more about any of the clinical and research studies below or would like to volunteer as a research subject, please email: rita.kohen@muhc.mcgill.ca.

The following 4 studies are part of NIH-NIDDK IBD Genetics Consortium (IBDGC)

  1. Identifying genes responsible for inflammatory bowel disease
  2. Mechanisms of microbiota in mucosal inflammation across the biologic demarcation of Ulcerative Colitis
  3. Mechanisms of intestinal inflammation following ileal resection for Crohn’s Disease
  4. Understanding the Genetics of Inflammatory Bowel Disease: The Diversity Study

Sponsor: Dr. John D. Rioux, Montreal Heart Institute
Funding:  Génome Canada (Rioux), National Institutes of Health (Rioux) and Pfizer Canada Inc. (Rioux)

Study Title: iGenoMed – CHUM: Identification of biomarkers of response to molecularly-targeted therapies in inflammatory bowel diseases


Study Title: Inflammatory Bowel Disease Epidemiology, Future Burden and Cancer Risk in Québec and Canada

as part of an initiative by the Canadian Gastro-Intestinal Epidemiology Consortium – pending approval


Collaboration with Dr. Jose Teodoro, McGill University

Study Title: Modulation of fatty acid esters of hydroxy fatty acids (FAHFA) levels in the intestine via G0S2 inhibition

Dr. Alain Bitton & Dr. Terry Sigman


Sponsor: Dr. Kenneth Croitoru, Mount Sinai Hospital, Toronto ON with funding from Crohn’s and Colitis Canada

Study Title: A Multidisciplinary Human Study on the Genetic, Environmental and Microbial Interactions that Cause IBD (GEM Project)

Dr. Peter Lakatos


If you are interested in learning more about any of the clinical and research studies below or would like to volunteer as a research subject, please email: rita.kohen@muhc.mcgill.ca

Study Title: Clinical Efficacy and Safety Following Start of Guselkumab, Risankizumab or Upadacitinib Advanced Targeted Therapy in Patients with Inflammatory Bowel Disease (pending ethics approval)


Study Title: Clinical Outcomes and Therapeutic Drug Monitoring Following New Start or Switching from Infliximab Originator to Subcutaneous Biosimilars in Patients with Inflammatory Bowel Disease: an Observational Study


Collaboration with Dr. Derek Rosenzweig, McGill University

Study Title: Biofabrication of a 3D gut-on-a-chip model of human inflammatory bowel disease

Your donations help deliver specialized and quality care to people with inflammatory bowel disease (IBD) in Quebec.

Your generosity benefits the IBD clinics at the Montreal General Hospital, the Montreal Children's Hospital and the Jewish General Hospital.

Donate